Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Capsule + Anti-PD-1 in Resistant GI Cancers
NCT04130763Phase 1Completed
- Sponsor
- Peking University
- Start
- Dec 2019
- Primary completion
- Feb 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Fecal Microbiota Transplantation capsules in gastrointestinal cancer, sponsored by Peking University. Primary endpoints: Objective Response Rate at 14 weeks, Number of Adverse Events at 1 week and 1 more. Started Dec 2019; status: completed.
02
Drugs
Fecal Microbiota Transplantation capsules
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT04130763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04130763.